Search

Author/Creator Caccese, M

1. 1417PPreliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations. (23rd October 2018)

Authors:
Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 374OMismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics. (23rd October 2018)

Authors:
Lombardi, G; Caccese, M; Simonelli, M; Fassan, M; Persico, P; Lorenzi, E; Bertorelle, R; Gardiman, M P; Bellu, L; Pambuku, A; Santoro, A; Zagonel, V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>. (19th September 2018)

Authors:
Lombardi, G; de Salvo, G; Rudà, R; Franceschi, E; Eoli, M; Faedi, M; Pace, A; Lolli, I; Rizzato, S; Germano, D; Pasqualetti, F; Farina, M; Magni, G; Bellu, L; Caccese, M; Pambuku, A; Bergo, E; Indraccolo, S; Gardiman, M; Soffietti, R
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii219
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. (6th September 2019)

Authors:
Lombardi, G; Del Bianco, P; Brandes, A; Eoli, M; Rudà, R; Ibrahim, T; Lolli, I; Pace, A; Daniele, B; Pasqualetti, F; Rizzato, S; Bergo, E; Caccese, M; Padovan, M; Soffietti, R; De Salvo, G; Zagonel, V
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 3
Page Start:
iii14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>. (19th September 2018)

Authors:
Lombardi, G; Indraccolo, S; de Salvo, G; Verza, M; Magni, G; Eoli, M; Rudà, R; Franceschi, E; Faedi, M; Lolli, I; Rizzato, S; Caccese, M; Gardiman, M; Zagonel, V
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>. (19th September 2018)

Authors:
Lombardi, G; Indraccolo, S; de Salvo, G; Verza, M; Magni, G; Eoli, M; Rudà, R; Franceschi, E; Faedi, M; Lolli, I; Rizzato, S; Caccese, M; Gardiman, M; Zagonel, V
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P02.02.A Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience. (5th September 2022)

Authors:
Padovan, M; Maccari, M; Bosio, A; Vizzaccaro, S; Cestonaro, I; Corrà, M; Caccese, M; Cerretti, G; Fassan, M; Zagonel, V; Lombardi, G
Journal:
Neuro-oncology
Issue:
Volume 24(2022)Supplement 2
Page Start:
ii29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗